Gt biopharma to participate in the h.c. wainwright cell therapy virtual conference

Brisbane, california, feb. 24, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced that dr. jeffrey miller, md, gt bipharma's consulting chief medical officer and chief scientific officer, will present a corporate overview at h.c. wainwright's cell therapy virtual conference taking place on february 28, 2023. company management will also be participating in 1x1 meetings during the event.
GTBP Ratings Summary
GTBP Quant Ranking